4d Pharma PLC 4D pharma to host virtual KOL event (0204Z)
January 20 2022 - 1:00AM
UK Regulatory
TIDMDDDD
RNS Number : 0204Z
4d Pharma PLC
20 January 2022
4D pharma to Host Virtual KOL Event Discussing Asthma Treatment
Landscape and Review of Positive Topline Results from Part A of
Phase I/II Trial of MRx-4DP0004
Leeds, UK, January 20, 2022 - 4D pharma plc (AIM: DDDD, NASDAQ:
LBPS) , a pharmaceutical company leading the development of Live
Biotherapeutic products (LBPs), a novel class of drug derived from
the microbiome, today announced that it will host a virtual Key
Opinion Leader (KOL) event to review previously disclosed positive
topline results from Part A of its Phase I/II trial of MRx-4DP004
for the treatment of asthma and to discuss the asthma treatment
landscape. The event will take place on Thursday, January 27, 2022,
from 8:00 a.m. ET (1:00 p.m. GMT).
The event will feature presentations from 4D pharma management
and KOL, Professor Chris Brightling, National Institute for Health
Research (NIHR) Senior Investigator and Clinical Professor in
Respiratory Medicine, Department of Respiratory Sciences,
University of Leicester, UK, and Principle Investigator of the
MRx-4DP0004 Phase I/II trial.
A live webcast of the event will be available on the Reports and
Presentations section of the 4D Pharma website at
www.4dpharmaplc.com . A replay of the webcast and accompanying
slides will be available on the 4D pharma website following the
event.
About 4D pharma
4D pharma is a world leader in the development of Live
Biotherapeutics, a novel and emerging class of drugs, defined by
the FDA as biological products that contain a live organism, such
as a bacterium, that is applicable to the prevention, treatment or
cure of a disease. 4D has developed a proprietary platform,
MicroRx(R), that rationally identifies Live Biotherapeutics based
on a deep understanding of function and mechanism. 4D pharma's Live
Biotherapeutic products (LBPs) are orally delivered single strains
of bacteria that are naturally found in the healthy human gut. The
Company has five clinical programs, namely a Phase I/II study of
MRx0518 in combination with KEYTRUDA(R) (pembrolizumab) in solid
tumors, a Phase I study of MRx0518 in a neoadjuvant setting for
patients with solid tumors, a Phase I study of MRx0518 in patients
with pancreatic cancer, a Phase I/II study of MRx-4DP0004 in
asthma, and Blautix(R) in Irritable Bowel Syndrome (IBS) which has
completed a successful Phase II trial. Preclinical-stage programs
include candidates for CNS disease such as Parkinson's disease and
other neurodegenerative conditions. The Company has a research
collaboration with MSD, a tradename of Merck & Co., Inc.,
Kenilworth, NJ, USA, to discover and develop Live Biotherapeutics
for vaccines.
For more information, refer to https://www.4dpharmaplc.com
Contact Information:
4D
Duncan Peyton, Chief Executive Officer +44 (0)113 895 0130
Investor Relations ir@4dpharmaplc.com
Singer Capital Markets - Nominated Adviser and Joint Broker +44
(0)20 7496 3000
Philip Davies / James Fischer (Corporate Finance)
Tom Salvesen (Corporate Broking)
Bryan Garnier & Co. Limited - Joint Broker +44 (0)20 7332
2500
Dominic Wilson
Stern Investor Relations
Julie Seidel +1-212-362-1200
Julie.seidel@sternir.com
Image Box Communications
Neil Hunter / Michelle Boxall +44 (0)20 8943 4685
6 Degrees
Lynne Dardanell +1-336-202-9689
ldardanell@6degreespr.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCGPUGAGUPPGBB
(END) Dow Jones Newswires
January 20, 2022 02:00 ET (07:00 GMT)
4d Pharma (LSE:DDDD)
Historical Stock Chart
From Mar 2024 to Apr 2024
4d Pharma (LSE:DDDD)
Historical Stock Chart
From Apr 2023 to Apr 2024
